{"id":"NCT02124564","sponsor":"UCB Japan Co. Ltd.","briefTitle":"A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures","officialTitle":"Multicenter, Open-Label, Long-Term Study to Investigate the Safety of Conversion to Lacosamide at Doses up to 600 mg/Day as Monotherapy in Japanese Adults With Partial-Onset Seizures With or Without Secondary Generalization","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2017-11-21","completion":"2017-11-21","firstPosted":"2014-04-28","resultsPosted":"2019-06-28","lastUpdate":"2019-10-28"},"enrollment":19,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Partial-onset Seizures"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":["Vimpat"]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"}],"summary":"This study is to evaluate the long-term safety and tolerability of Lacosamide (LCM) 200 mg/day to LCM 600 mg/day taken in monotherapy in Japanese subjects who currently have partial-onset seizures with or without secondary generalization and who are treated with a single Anti-Epileptic Drug (AED) with marketing approval in Japan.","primaryOutcome":{"measure":"Number of Subjects With at Least One Incidence of Treatment-Emergent Adverse Events (TEAEs) During the Study","timeFrame":"From the Titration Period (investigational product is taken) to the End of Study Visit (up to 3.5 years)","effectByArm":[{"arm":"Lacosamide (Safety Set)","deltaMin":19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":19},"commonTop":["Dizziness","Somnolence","Nasopharyngitis","Vertigo","Headache"]}}